Early-stage breast cancer diagnosis can greatly reduce overall breast cancer mortality rates in the long term. Currently, the most important variable for prediction of outcome is to correctly identify early-stage disease cells in the body. Although experts agree that a chest x-ray may be able to detect small changes or growths early in the disease, accurate diagnosis is dependent on tissue sampling and imaging studies. However, mammography is the gold standard for early breast cancer detection. Mammography is the definitive method for detecting any breast cancers that are not evident with X-rays alone. This diagnostic test involves the use of electromagnetic radiation for a variety of tissue samples.

The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/425

Drivers

Increasing occurrences of breast cancer coupled with the advent of the advanced imaging equipment are expected to stimulate growth of the breast cancer diagnostic market throughout the forecast period.

Moreover, increasing involvement of the government in providing insurance and reimbursement policies for early diagnosis of breast cancer is expected to propel growth of the breast cancer diagnostic market over the forecast period.

The Epitome of the COVID-19 Aftermath

The global breast cancer diagnostic market had suffered a setback with the onset of the COVID-19 virus. The evident decline in the number of cancer diagnostic and screenings have significantly slowed the progress of the market since mid-March 2020. Although, the gradual ease in pandemic-led restrictions is providing a breath of relief for the market players. Furthermore, the advent of hybrid screening solutions will play a high-leveraging role in the revival of the market.

Key Trends

  • The breast cancer diagnostic market is anticipated to grow at a CAGR of XX % during the forecast period owing to the rising cases of breast cancer and increasing government efforts. For instance, according to the Centers for Disease Control and Prevention (CDC), over 250,000 U.S. women were diagnosed with breast cancer in 2020.

  • By expanding the horizon, the breast cancer diagnostic market in the North American region is slated to propel significantly on the back of higher occurrences of breast cancer coupled with the availability of advanced diagnostic and screening equipment for treatment.

  • In parallel, the Asia Pacific is sustaining well for the breast cancer diagnostic market on the heels of increasing awareness over early detection of breast cancer combined with the introduction of lucrative compensation policies.

Top Key Players Include In Breast Cancer Diagnostic Market: Hologic Inc., GE Healthcare, Phillips Healthcare, Fujifilm Holdings Corporation, Gamma Medica Inc., Toshiba Corporation, Aurora Imaging Technology Inc., and Dilion Technologies Inc. GE Healthcare

Buy This Research Study Report For Quick Access With Flat US $ 2000 Off@ https://www.coherentmarketinsights.com/promo/buynow/425

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: [email protected]